Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.
Humans
Ischemic Stroke
/ epidemiology
Fibrinolytic Agents
/ therapeutic use
Brain Ischemia
/ complications
Cohort Studies
Thrombolytic Therapy
/ adverse effects
Treatment Outcome
COVID-19
/ complications
Stroke
/ epidemiology
Intracranial Hemorrhages
/ etiology
Cerebral Hemorrhage
/ complications
Endovascular Procedures
/ adverse effects
Registries
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
14 02 2023
14 02 2023
Historique:
received:
27
04
2022
accepted:
23
09
2022
pubmed:
10
11
2022
medline:
16
2
2023
entrez:
9
11
2022
Statut:
ppublish
Résumé
COVID-19-related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19. This was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT). Of a total of 15,128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19; of those, 5,848 (38.7%) patients received IVT-only and 9,280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted OR 1.53; 95% CI 1.16-2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20-2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23-1.99), 24-hour mortality (OR 2.47; 95% CI 1.58-3.86), and 3-month mortality (OR 1.88; 95% CI 1.52-2.33). Patients with COVID-19 also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26-1.60). Patients with AIS and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 patients receiving treatment. Current available data do not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in patients with COVID-19 or to establish different treatment recommendations in this subgroup of patients with ischemic stroke. Our findings can be taken into consideration for treatment decisions, patient monitoring, and establishing prognosis. The study was registered under ClinicalTrials.gov identifier NCT04895462.
Sections du résumé
BACKGROUND AND OBJECTIVES
COVID-19-related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19.
METHODS
This was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT).
RESULTS
Of a total of 15,128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19; of those, 5,848 (38.7%) patients received IVT-only and 9,280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted OR 1.53; 95% CI 1.16-2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20-2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23-1.99), 24-hour mortality (OR 2.47; 95% CI 1.58-3.86), and 3-month mortality (OR 1.88; 95% CI 1.52-2.33). Patients with COVID-19 also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26-1.60).
DISCUSSION
Patients with AIS and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 patients receiving treatment. Current available data do not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in patients with COVID-19 or to establish different treatment recommendations in this subgroup of patients with ischemic stroke. Our findings can be taken into consideration for treatment decisions, patient monitoring, and establishing prognosis.
TRIAL REGISTRATION INFORMATION
The study was registered under ClinicalTrials.gov identifier NCT04895462.
Identifiants
pubmed: 36351814
pii: WNL.0000000000201537
doi: 10.1212/WNL.0000000000201537
pmc: PMC9969910
doi:
Substances chimiques
Fibrinolytic Agents
0
Banques de données
ClinicalTrials.gov
['NCT04895462']
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e739-e750Informations de copyright
© 2022 American Academy of Neurology.
Références
J Neurointerv Surg. 2020 Jul;12(7):648-653
pubmed: 32451359
Stroke. 2021 Jan;52(1):48-56
pubmed: 33280551
Brain. 2020 Oct 1;143(10):3089-3103
pubmed: 32645151
Mayo Clin Proc Innov Qual Outcomes. 2022 Apr;6(2):156-165
pubmed: 35079695
Stroke. 2018 Mar;49(3):660-666
pubmed: 29459390
Stroke. 2021 Mar;52(3):1079-1082
pubmed: 33467881
Eur J Neurol. 2020 Dec;27(12):2641-2645
pubmed: 32905639
Stroke. 2020 Aug;51(8):2540-2543
pubmed: 32466736
Stroke. 2021 Jan;52(1):31-39
pubmed: 33222617
Stroke. 2021 May;52(5):1895-1904
pubmed: 33794655
J Neurol Neurosurg Psychiatry. 2021 Mar;92(3):242-248
pubmed: 33154179
Blood. 2016 Nov 17;128(20):2423-2434
pubmed: 27531677
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
AJNR Am J Neuroradiol. 2020 Nov;41(11):2012-2016
pubmed: 32816767
Stroke. 2021 Jan;52(2):552-562
pubmed: 33406872
J Neurol Sci. 2017 Oct 15;381:95-99
pubmed: 28991723
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Eur J Neurol. 2021 Nov;28(11):3826-3836
pubmed: 34224187
Stroke. 2021 May;52(5):1826-1829
pubmed: 33728926
J Neurol. 2021 Oct;268(10):3561-3568
pubmed: 33683456
Stroke. 2020 Sep;51(9):e254-e258
pubmed: 32787707
Int J Stroke. 2013 Dec;8(8):632-8
pubmed: 23590464
Lancet. 1998 Oct 17;352(9136):1245-51
pubmed: 9788453
Eur J Neurol. 2022 Mar;29(3):732-743
pubmed: 34845794
J Stroke Cerebrovasc Dis. 2021 Dec;30(12):106121
pubmed: 34601242
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288